Loading…
Zymeworks Inc. is projected to rise to $31.35 by 2027, a +37% move from its current price of $22.86. ZYME is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/25/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 26 | $22.39 | $22.88 | $23.39 | +0.09% |
| Jul 27 | $22.21 | $22.90 | $23.62 | +0.19% |
| Jul 28 | $22.07 | $22.92 | $23.81 | +0.28% |
| Jul 29 | $21.97 | $22.95 | $23.97 | +0.38% |
| Jul 30 | $21.87 | $22.97 | $24.12 | +0.47% |
| Jul 31 | $21.79 | $22.99 | $24.25 | +0.57% |
| Aug 1 | $21.72 | $23.01 | $24.38 | +0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.72 | $23.01 | $24.38 | +0.66% |
| Week 2 | $21.35 | $23.16 | $25.14 | +1.33% |
| Week 3 | $21.10 | $23.32 | $25.77 | +2.00% |
| Week 4 | $20.91 | $23.47 | $26.35 | +2.67% |
| Week 5 | $20.76 | $23.63 | $26.89 | +3.35% |
| Week 6 | $20.64 | $23.78 | $27.40 | +4.03% |
| Week 7 | $20.55 | $23.94 | $27.89 | +4.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zymeworks Inc. is a biotechnology company focused on developing biotherapeutics for cancer, inflammation, and autoimmune diseases. Its platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3-expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol-Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc.
Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Zymeworks Inc. (ZYME) is a biotechnology company in the healthcare sector with a current price of $24.19 and a market capitalization of $1.78B. The company ranks 2102 by market cap.
The stock trades near its technical benchmarks, with a 50-day moving average of $24.64 and a 200-day moving average of $23.65, indicating price positioning close to notable support and resistance levels.
A major floor 14.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.6% away) — a key level to hold.
The nearest ceiling, 18.4% above — a clean break opens room to run.
A major ceiling 26.0% above — clearing it would confirm fresh momentum.
Key ZYME support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZYME market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.70 | Sell | $23.67 | Sell |
| MA 10 | $24.28 | Sell | $24.15 | Sell |
| MA 20 | $24.94 | Sell | $24.46 | Sell |
| MA 50 | $24.44 | Sell | $24.67 | Sell |
| MA 100 | $25.07 | Sell | $24.50 | Sell |
| MA 200 | $23.82 | Sell | $22.97 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.93 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -117.55 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.28 | Sell |
| ROC (12) | -13.47 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.04 | Buy |
| Awesome (5,34) | -0.64 | Sell |
| Ultimate (7,14,28) | 23.16 | Buy |
| Momentum (10) | -3.95 | Sell |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 23.27 | Sell |
| ADX (14) | 14.50 | Neutral |
| ATR (14) | 0.49 | Info |
The 30-day technical picture shows bullish sentiment, with RSI14 at 40 and the price trading near, but slightly below, the 50-day moving average of $24.64. The 200-day moving average sits at $23.65, providing a baseline for longer-term trend interpretation. The current 30-day price range spans from $20.67 to $28.31, highlighting near-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.02 | $22.86 | $34.01 | 0% | Neutral | |
| $25.45 | $31.35 | $40.55 | +37% | Bullish | |
| $28.91 | $36.41 | $48.56 | +59% | Bullish | |
| $32.35 | $41.49 | $56.69 | +82% | Bullish | |
| $33.42 | $43.55 | $60.73 | +91% | Bullish | |
| $37.43 | $49.49 | $70.25 | +116% | Bullish | |
| $41.98 | $56.24 | $81.13 | +146% | Bullish | |
| $49.56 | $67.22 | $98.39 | +194% | Bullish | |
| $57.86 | $79.42 | $117.81 | +247% | Bullish | |
| $59.33 | $82.35 | $123.69 | +260% | Bullish | |
| $89.77 | $131.05 | $207.46 | +473% | Bullish | |
| $163.65 | $260.08 | $444.80 | +10.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $22.02 | $22.86 | $27.13 | +0.00% |
| August 2026 | $20.78 | $24.33 | $29.09 | +6.42% |
| September 2026 | $21.15 | $24.91 | $30.09 | +2.40% |
| October 2026 | $21.44 | $25.38 | $30.91 | +1.87% |
| November 2026 | $22.37 | $26.59 | $32.60 | +4.79% |
| December 2026 | $23.10 | $27.57 | $34.01 | +3.67% |
Click any year to see its month-by-month ZYME forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Zymeworks Inc.'s 2026 outlook centres on $22.86, within a $22.02 to $34.01 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ZYME could reach as high as $40.55, with a base case around $31.35 and support toward $25.45 — roughly +37% from $22.86. Buyers look set to stay in control over this stretch.
Expect ZYME to range from $28.91 to $48.56 through 2028. The $36.41 average target implies a +59% move from current prices. That is up +16% on the projected 2027 average. Momentum favours further upside here.
The ZYME price prediction for 2029 points to an average of $41.49 (low $32.35, high $56.69) — a potential gain of +82% on today's $22.86. Buyers look set to stay in control over this stretch.
In 2030, ZYME is projected to trade between $33.42 and $60.73, averaging $43.55 — a potential gain of +91% from today's $22.86. That is up +5% on the projected 2029 average. Momentum favours further upside here.
Zymeworks Inc.'s 2031 outlook centres on $49.49, within a $37.43 to $70.25 range. That is up +14% on the projected 2030 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ZYME could reach as high as $81.13, with a base case around $56.24 and support toward $41.98 — roughly +146% from $22.86. Momentum favours further upside here.
Expect ZYME to range from $49.56 to $98.39 through 2033. The $67.22 average target implies a +194% move from current prices. That is up +20% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ZYME price prediction for 2034 points to an average of $79.42 (low $57.86, high $117.81) — a potential gain of +247% on today's $22.86. Momentum favours further upside here.
In 2035, ZYME is projected to trade between $59.33 and $123.69, averaging $82.35 — a potential gain of +260% from today's $22.86. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Zymeworks Inc.'s 2040 outlook centres on $131.05, within a $89.77 to $207.46 range. That is up +59% on the projected 2035 average. That marks a +473% change versus current levels. Momentum favours further upside here.
By 2050, ZYME could reach as high as $444.80, with a base case around $260.08 and support toward $163.65 — roughly +10.4x from $22.86. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZYME today (≈ 43.744532 ZYME) could be worth
$11,376.91
+$10,376.91 (+1038%) by 2050 · US Dollar
Based on the average projected ZYME price of $260.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZYMEwould be worth at today's price.
$1,000 invested in ZYME on Jul 23, 2025 (≈ 69.979006 ZYME) would be worth
$1,599.72
+$599.72 (+60.0%) today · 1.60× · US Dollar
Based on a ZYME entry price of $14.29 vs. today's $22.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.19 | $945.02 | -5.5% |
| 1 month ago | $23.88 | $957.29 | -4.3% |
| 3 months ago | $28.1 | $813.52 | -18.6% |
| 6 months ago | $23.24 | $983.65 | -1.6% |
| 1 year ago | $14.29 | $1,599.72 | +60.0% |
| All time (5.0y) ago | $33.45 | $683.41 | -31.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZYME forecast.
Our base-case forecast reaches $46.00 around 2031.
Implied market cap at $46.00: $3.36B
The multi-year forecast outlines a bullish trajectory, with the average price rising across years and substantial growth in ROI. The 2026 forecast lists an average of $24.19 with an ROI of 0 and a range from $22.02 to $36.66. By 2027, the average is $33.37 with ROI 37.9; 2028 average $39.09 with ROI 61.6; 2029 average $44.23 with ROI 82.9; 2030 average $45.90 with ROI 89.7.
The path continues to 2031 ($52.62, ROI 117.5), 2032 ($59.58, ROI 146.3), 2033 ($71.61, ROI 196), 2034 ($85.52, ROI 253.5), and 2035 ($87.10, ROI 260.1). The forecast then projects, into 2040, an average of $140.91 (ROI 482.5) and, by 2050, an average of $273.99 (ROI 1032.7). The sentiment remains bullish across these horizons, but the asset also carries notable risk reflected in an annualized volatility of 50%.
These figures are estimates and not guarantees of future results.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $45.90 with a min of $34.77 and a max of $65.03, and an ROI of 89.7, with a bullish sentiment.
The outlook exhibits a bullish trajectory with rising average prices and escalating ROI through 2050 (e.g., 2027 avg $33.37, 2030 avg $45.90, 2040 avg $140.91, 2050 avg $273.99 and ROI up to 1032.7). These are estimates and not guarantees.
Yes. The forecast shows possible outcomes where the max price reaches $106.86 in 2033, with other years projecting higher maximums (e.g., 2040 max $228.65, 2050 max $482.69).
The current price is $24.19 and the market capitalization is $1.78B.
Overall sentiment is BULLISH. RSI14 is 40, SMA50 is $24.64, and SMA200 is $23.65. The 30-day range is $20.67 to $28.31, with support at $22.49 and resistance at $27.07.
Zymeworks Inc. Community Discussion
0Share your Zymeworks Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.